Munich - Delayed Quote EUR

Genprex Inc (2DE0.MU)

Compare
0.5400 0.0000 (0.00%)
At close: October 21 at 11:12 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 2DE0.MU

Recent News: 2DE0.MU

View More
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa

Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa
Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa? Gene Therapy in Combination with Tecentriq? in Extensive Stage Small Cell Lung Cancer

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa? Gene Therapy in Combination with Tecentriq? in Extensive Stage Small Cell Lung Cancer
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa? Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa? Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Genprex Collaborators to Present Positive Preclinical Data on Reqorsa? Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa? Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes
Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Genprex Announces Formation of Mesothelioma Clinical Advisory Board
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
View More

Related Tickers